Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - vancomycin hydrochloride, quantity: 1025 mg (equivalent: vancomycin, qty 1000 mg) - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin hydrochloride for intravenous infusion is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial medicine, including the penicillins and cephalosporins. vancomycin is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly. vancomycin is effective alone or in combination with an aminoglycoside for endocarditis caused by strep. viridans or strep. bovis. for endocarditis caused by enterococci (eg enterococcus faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by staph. epidermidis or diphtheroids. the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures. specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Israel - English - Ministry of Health

genmedix , israel - vancomycin as hydrochloride - lyophilized powder for concentrated solution - vancomycin as hydrochloride 500 mg/vial - vancomycin - vancomycin - vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-iactam-resistant) staphylococci. it is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs.vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal infections are purulent and localized. for endocarditis due to streptococcus viridans or streptococcus bovis vancomycin hydrochloride has been shown to be effective in combination with an aminoglycoside. vancomycin hydrochloride has been shown to be effective only in combination with an aminoglycoside for endocarditis due to enterococci (eg enterococcus fecalis). vancomycin hydrochloride has been shown to be effective for the treatment of diphtheroid endocareditis. in early-onset prosthetic valve endocarditis caused by staphylococcus epidermidis or diptheroids vancomycin hydrochloride has been administered successfully in combination with either rifampin an aminoglycoside or combined with both drugs. bacteriologic cultures of specimens should be obtained for isolation and identification of causative organisms and determination of susceptibilities to vancomycin hydrochloride. oral therapy vancomycin hydrochloride injection may be given orally for the treatment of antibiotic-associated pseudomembrannous colitis due to staphylococcus enterocolitis and clostridium difficile. vancomycin hydrochloride is not effective orally when administered for other types of infection.

Israel - English - Ministry of Health

genmedix , israel - vancomycin as hydrochloride - lyophilized powder for concentrated solution - vancomycin as hydrochloride 1000 mg/vial - vancomycin - vancomycin - vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-iactam-resistant) staphylococci. it is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs.vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal infections are purulent and localized. for endocarditis due to streptococcus viridans or streptococcus bovis vancomycin hydrochloride has been shown to be effective in combination with an aminoglycoside. vancomycin hydrochloride has been shown to be effective only in combination with an aminoglycoside for endocarditis due to enterococci (eg enterococcus fecalis). vancomycin hydrochloride has been shown to be effective for the treatment of diphtheroid endocareditis. in early-onset prosthetic valve endocarditis caused by staphylococcus epidermidis or diptheroids vancomycin hydrochloride has been administered successfully in combination with either rifampin an aminoglycoside or combined with both drugs. bacteriologic cultures of specimens should be obtained for isolation and identification of causative organisms and determination of susceptibilities to vancomycin hydrochloride. oral therapy vancomycin hydrochloride injection may be given orally for the treatment of antibiotic-associated pseudomembrannous colitis due to staphylococcus enterocolitis and clostridium difficile. vancomycin hydrochloride is not effective orally when administered for other types of infection.

Israel - English - Ministry of Health

genmedix , israel - vancomycin as hydrochloride - lyophilized powder for concentrated solution - vancomycin as hydrochloride 500 mg/vial - vancomycin - vancomycin - vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-iactam-resistant) staphylococci. it is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. antibiotic therapy is as an adjunct to appropriate surgical measures when sta

Israel - English - Ministry of Health

genmedix , israel - vancomycin as hydrochloride - lyophilized powder for concentrated solution - vancomycin as hydrochloride 1 g/vial - vancomycin - vancomycin - vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-iactam-resistant) staphylococci. it is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. antibiotic therapy is as an adjunct to appropriate surgical measures when stap

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - vancomycin hydrochloride, quantity: 512.5 mg (equivalent: vancomycin, qty 500 mg) - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin hydrochloride for intravenous infusion is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial medicine, including the penicillins and cephalosporins. vancomycin is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly. vancomycin is effective alone or in combination with an aminoglycoside for endocarditis caused by strep. viridans or strep. bovis. for endocarditis caused by enterococci (eg enterococcus faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by staph. epidermidis or diphtheroids. the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures. specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - vancomycin hydrochloride, quantity: 268 mg (equivalent: vancomycin, qty 250 mg) - capsule, hard - excipient ingredients: macrogol 6000; titanium dioxide; brilliant blue fcf; maize starch; purified water; purified talc; iron oxide yellow; gelatin; sodium lauryl sulfate; ethanol; shellac; carnauba wax; 1-butanol; glyceryl monooleate - vancomycin bnm capsules may be administered orally for the treatment of staphylococcal enterocolitis and antibiotic-associated pseudomembranous colitis produced by c. difficile. parenteral administration of vancomycin is not effective for the above indications; therefore vancomycin bnm must be given orally. vancomycin bnm is not effective by the oral route for other types of infection.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - vancomycin hydrochloride, quantity: 134 mg (equivalent: vancomycin, qty 125 mg) - capsule, hard - excipient ingredients: macrogol 6000; titanium dioxide; ethanol; shellac; carnauba wax; 1-butanol; glyceryl monooleate; brilliant blue fcf; maize starch; purified water; purified talc; gelatin; sodium lauryl sulfate; tartrazine - vancomycin bnm capsules may be administered orally for the treatment of staphylococcal enterocolitis and antibiotic-associated pseudomembranous colitis produced by c. difficile. parenteral administration of vancomycin is not effective for the above indications; therefore vancomycin bnm must be given orally. vancomycin bnm is not effective by the oral route for other types of infection.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - vancomycin hydrochloride, quantity: 952 mg (equivalent: vancomycin, qty 1000000 iu) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - vancomycin juno is indicated in potentially life-threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin juno is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin juno is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g. e. faecalis), vancomycin juno is effective only in combination with an aminoglycoside. vancomycin juno is effective for the treatment of diphtheroid endocarditis. vancomycin juno is used in combination with rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin juno has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia, and soft tissue infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin juno.,vancomycin juno should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis produced by c. difficile. parenteral administration of vancomycin juno alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - vancomycin hydrochloride, quantity: 476 mg (equivalent: vancomycin, qty 500000 iu) - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin juno is indicated in potentially life-threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin juno is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin juno is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g. e. faecalis), vancomycin juno is effective only in combination with an aminoglycoside. vancomycin juno is effective for the treatment of diphtheroid endocarditis. vancomycin juno is used in combination with rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin juno has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia, and soft tissue infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin juno.,vancomycin juno should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis produced by c. difficile. parenteral administration of vancomycin juno alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.